BSX · Boston Scientific Corp
$51.83
+0.14 (+0.27%)
At close · Aug 14
Market Cap
$75.11B
Shares
1.45B
Boston Scientific Corp Earnings Call Transcripts
Every quarterly earnings call for Boston Scientific Corp (BSX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲3.7%
$3.24B
$140.00M
'22 Q4
23-02-01
▲12%
$3.39B
$314.00M
'23 Q1
23-04-26
▲10.9%
$3.60B
$270.00M
'23 Q2
23-07-27
▲11.3%
$3.53B
$504.00M
'23 Q3
23-10-26
▲14.9%
$3.73B
$504.00M
'23 Q4
24-01-31
▲13.8%
$3.86B
$493.00M
'24 Q1
24-04-24
▲14.5%
$4.12B
$322.00M
'24 Q2
24-07-24
▲19.3%
$4.21B
$468.00M
'24 Q3
24-10-23
▲22.5%
$4.56B
$563.00M
'24 Q4
25-02-05
▲20.9%
$4.66B
$672.00M
'25 Q1
25-04-23
▲22.8%
$5.06B
$795.00M
'25 Q2
25-07-23
▲20.3%
$5.07B
$755.00M
'25 Q3
25-10-22
▲15.8%
$5.29B
$670.00M
'25 Q4
26-02-04
▲11.6%
$5.20B
$1.34B
'26 Q1
26-04-22
LATEST
▲7.5%
$5.44B
$905.00M
'26 Q2
26-07-29
Earnings call
FY26 · Q3
2026-10-28
Boston Scientific Conference Call Discussing Third Quarter Financial Results
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-10
Boston Scientific at Wells Fargo’s 21st Annual Healthcare Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-29
Boston Scientific Corp Q2 FY2026 Earnings Call
Cautious tone
Watchman/LAAC Market Slowdown
Penumbra Acquisition
Neuromodulation Growth
Revenue
$5.44B
▲ 7.5% YoY Diluted EPS
$0.61
▲ 15.1% YoY Gross margin
70.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-27
Boston Scientific at Bernstein Annual Strategic Decisions Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-22
Boston Scientific Corp Q1 FY2026 Earnings Call
Cautious tone
WATCHMAN and PFA momentum
Urology and sacral neuromodulation
Penumbra acquisition and capital allocation
Revenue
$5.20B
▲ 11.6% YoY Diluted EPS
$0.90
▲ 100% YoY Gross margin
69.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-04
Boston Scientific Corp Q4 FY2025 Earnings Call
Confident tone
WATCHMAN & Structural Heart
M&A and Pending Acquisitions
Regional Growth (U.S., Europe, Asia Pac)
Revenue
$5.29B*
▲ 15.8% YoY Gross margin
69.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-22
Boston Scientific Corp Q3 FY2025 Earnings Call
Confident tone
EP / FARAPULSE momentum and ASCs
Quarterly financial outperformance
M&A and portfolio expansion
Revenue
$5.07B
▲ 20.3% YoY Diluted EPS
$0.51
▲ 59.4% YoY Gross margin
69.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-23
Boston Scientific Corp Q2 FY2025 Earnings Call
Confident tone
Concomitant Procedures and EP Portfolio
Cardiovascular and Cardiology Growth
Regional Performance (U.S., EMEA, Asia Pacific)
Revenue
$5.06B
▲ 22.8% YoY Diluted EPS
$0.53
▲ 140.9% YoY Gross margin
67.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-23
Boston Scientific Corp Q1 FY2025 Earnings Call
Confident tone
Tariffs and tax/Pillar 2 outlook
FARAPULSE and EP franchise
Manufacturing footprint and U.S. investment
Revenue
$4.66B
▲ 20.9% YoY Diluted EPS
$0.45
▲ 36.4% YoY Gross margin
68.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-05
Boston Scientific Corp Q4 FY2024 Earnings Call
Confident tone
2025 financial guidance and outlook
China and VBP pricing pressures
Farapulse / EP franchise momentum
Revenue
$4.56B*
▲ 22.5% YoY Gross margin
67.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-23
Boston Scientific Corp Q3 FY2024 Earnings Call
Confident tone
FARAPULSE PFA and AF Solutions
WATCHMAN Franchise
China and Asia Pacific Dynamics
Revenue
$4.21B
▲ 19.3% YoY Diluted EPS
$0.32
▼ 5.9% YoY Gross margin
68.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-24
Boston Scientific Corp Q2 FY2024 Earnings Call
Confident tone
FARAPULSE and EP Growth
Product Launches and Pipeline
M&A and Pending Acquisitions
Revenue
$4.12B
▲ 14.5% YoY Diluted EPS
$0.22
▲ 22.2% YoY Gross margin
69.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-24
Boston Scientific Corp Q1 FY2024 Earnings Call
Confident tone
FARAPULSE launch and EP momentum
Organic revenue growth and raised guidance
Gross margin pressure and inventory charges
Revenue
$3.86B
▲ 13.8% YoY Diluted EPS
$0.33
▲ 57.1% YoY Gross margin
68.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-31
Boston Scientific Corp Q4 FY2023 Earnings Call
Confident tone
2024 guidance and outlook
Product launches and pipeline
Gross margin and margin expansion
Revenue
$3.73B*
▲ 14.9% YoY Gross margin
69.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-26
Boston Scientific Corp Q3 FY2023 Earnings Call
Revenue
$3.53B
▲ 11.3% YoY Diluted EPS
$0.34
▲ 183.3% YoY Gross margin
68.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-27
Boston Scientific Corp Q2 FY2023 Earnings Call
Revenue
$3.60B
▲ 10.9% YoY Diluted EPS
$0.18
▲ 5.9% YoY Gross margin
70.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-26
Boston Scientific Corp Q1 FY2023 Earnings Call
Revenue
$3.39B
▲ 12% YoY Diluted EPS
$0.21
▲ 200% YoY Gross margin
69.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-01
Boston Scientific Corp Q4 FY2022 Earnings Call
Revenue
$3.24B*
▲ 3.7% YoY Gross margin
68.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-26
Boston Scientific Corp Q3 FY2022 Earnings Call
Revenue
$3.17B
▲ 8.1% YoY Diluted EPS
$0.12
▼ 57.1% YoY Gross margin
69.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-27
Boston Scientific Corp Q2 FY2022 Earnings Call
Revenue
$3.24B
▲ 5.4% YoY Diluted EPS
$0.17
▲ 41.7% YoY Gross margin
68.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-27
Boston Scientific Corp Q1 FY2022 Earnings Call
Revenue
$3.03B
▲ 10% YoY Diluted EPS
$0.07
▼ 69.6% YoY Gross margin
68.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-02
Boston Scientific Corp Q4 FY2021 Earnings Call
Revenue
$3.13B*
▲ 15.5% YoY Gross margin
68.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-27
Boston Scientific Corp Q3 FY2021 Earnings Call
Revenue
$2.93B
▲ 10.3% YoY Diluted EPS
$0.28
Gross margin
69.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-27
Boston Scientific Corp Q2 FY2021 Earnings Call
Revenue
$3.08B
▲ 53.6% YoY Diluted EPS
$0.12
Gross margin
69.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
Boston Scientific Corp Q1 FY2021 Earnings Call
Revenue
$2.75B
▲ 8.2% YoY Diluted EPS
$0.23
▲ 2200% YoY Gross margin
67.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-03
Boston Scientific Corp Q4 FY2020 Earnings Call
Revenue
$2.71B*
▼ 6.7% YoY Gross margin
63.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-28
Boston Scientific Corp Q3 FY2020 Earnings Call
Revenue
$2.66B
▼ 1.8% YoY Diluted EPS
$-0.12
▼ 233.3% YoY Gross margin
67.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-29
Boston Scientific Corp Q2 FY2020 Earnings Call
Revenue
$2.00B
▼ 23.9% YoY Diluted EPS
$-0.11
▼ 200% YoY Gross margin
60.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-29
Boston Scientific Corp Q1 FY2020 Earnings Call
Revenue
$2.54B
▲ 2% YoY Diluted EPS
$0.01
▼ 96.7% YoY Gross margin
68.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-14
Boston Scientific Corp Q4 FY2019 Earnings Call
Revenue
$2.90B*
▲ 13.4% YoY Gross margin
70.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–30 of 30 earnings calls
Key facts
CIK
885725
CUSIP
101137107
13F (30d)
1360 filings
1300 filers
Visit website
Investor relations